WO2003048202A3 - Gène activant le facteur nucléaire kappa b - Google Patents

Gène activant le facteur nucléaire kappa b Download PDF

Info

Publication number
WO2003048202A3
WO2003048202A3 PCT/JP2002/012644 JP0212644W WO03048202A3 WO 2003048202 A3 WO2003048202 A3 WO 2003048202A3 JP 0212644 W JP0212644 W JP 0212644W WO 03048202 A3 WO03048202 A3 WO 03048202A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
dna
activating
recombinant vector
activation
Prior art date
Application number
PCT/JP2002/012644
Other languages
English (en)
Other versions
WO2003048202A2 (fr
Inventor
Akio Matsuda
Shuji Muramatsu
Original Assignee
Asahi Kasei Pharma Corp
Akio Matsuda
Shuji Muramatsu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2001368692A external-priority patent/JP2006166701A/ja
Priority claimed from JP2002291302A external-priority patent/JP2006166705A/ja
Application filed by Asahi Kasei Pharma Corp, Akio Matsuda, Shuji Muramatsu filed Critical Asahi Kasei Pharma Corp
Priority to AU2002349784A priority Critical patent/AU2002349784A1/en
Publication of WO2003048202A2 publication Critical patent/WO2003048202A2/fr
Publication of WO2003048202A3 publication Critical patent/WO2003048202A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

Cette invention a trait à des protéines capables d'activer le NF-λ B, utilisées pour le diagnostic, le traitement ou la prévention d'états pathologiques associés à une activation excessive ou à l'inhibition du NF-λ B. Grâce à l'utilisation d'un NF-λ B-Luc plasmidique, un ADNc capable d'activer le NF-λ B a été cloné à partir d'une banque d'ADNc issue de fibroblastes pulmonaires et analogue, puis la séquence d'ADN et la séquence aminoacide dérivée déterminées. La protéine, l'ADN codant cette protéine, un vecteur de recombinaison contenant cet ADN ainsi qu'un transformant contenant ce vecteur, se révèlent des plus utiles pour le criblage d'une substance inhibant le NF-λ B ou stimulant son activation.
PCT/JP2002/012644 2001-12-03 2002-12-03 Gène activant le facteur nucléaire kappa b WO2003048202A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002349784A AU2002349784A1 (en) 2001-12-03 2002-12-03 Nf-kappab activating genes

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP2001368692A JP2006166701A (ja) 2001-12-03 2001-12-03 ＮＦ−κＢ活性化遺伝子
JP2001-368692 2001-12-03
US33582901P 2001-12-05 2001-12-05
US60/335,829 2001-12-05
JP2002-291302 2002-10-03
JP2002291302A JP2006166705A (ja) 2002-10-03 2002-10-03 ＮＦ−κＢ活性化遺伝子
US41576902P 2002-10-04 2002-10-04
US60/415,769 2002-10-04

Publications (2)

Publication Number Publication Date
WO2003048202A2 WO2003048202A2 (fr) 2003-06-12
WO2003048202A3 true WO2003048202A3 (fr) 2004-07-01

Family

ID=27482716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/012644 WO2003048202A2 (fr) 2001-12-03 2002-12-03 Gène activant le facteur nucléaire kappa b

Country Status (2)

Country Link
AU (1) AU2002349784A1 (fr)
WO (1) WO2003048202A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
AU2003245990A1 (en) * 2002-06-26 2004-01-19 Bayer Healthcare Ag Regulation of human map kinase kinase kinase
AU2003301621A1 (en) * 2002-10-22 2004-05-13 Oregon Health And Science University Apoptotic response regulation through interaction of tripartite motif protein 32 with pias
AU2003290432A1 (en) * 2002-12-26 2004-07-22 Asahi Kasei Pharma Corporation T cell activating gene
WO2004106937A2 (fr) * 2003-06-02 2004-12-09 Bayer Healthcare Ag Diagnostic et therapeutique pour des maladies associees au recepteur 6 de purine p2y (p2y6) couple a la proteine g
WO2004111085A1 (fr) * 2003-06-10 2004-12-23 Xantos Biomedicine Ag Facteur angiogenique et son utilisation medicale
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1791565B1 (fr) 2004-09-23 2016-04-20 Genentech, Inc. Anticorps et conjugues produits avec de la cysteine
JP2007054042A (ja) * 2005-07-26 2007-03-08 Japan Science & Technology Agency インターフェロン誘導分子ｉｐｓ−１
EP2324044A4 (fr) * 2008-08-04 2012-04-25 Univ Miami Sting (stimulateur de gènes d interféron), un régulateur de réponses immunitaires innées
WO2010053877A2 (fr) * 2008-11-04 2010-05-14 The Regents Of The University Of Colorado, A Body Corporate Protéine associée au cmh ii et ses utilisations
JP2013504585A (ja) 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
KR101738203B1 (ko) 2010-04-15 2017-05-19 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
CA3220104A1 (fr) 2010-06-08 2011-12-15 Genentech, Inc. Anticorps et conjugues modifies par la cysteine
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
JP5987053B2 (ja) 2011-05-12 2016-09-06 ジェネンテック， インコーポレイテッド フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングｌｃ−ｍｓ／ｍｓ法
CN103030688B (zh) * 2011-09-30 2014-09-17 北京大学 抑制癌细胞生长的短肽及其编码基因与应用
EP2750713B1 (fr) 2011-10-14 2015-09-16 Spirogen Sàrl Pyrrolobenzodiazépines et conjugués associés
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
HUE042731T2 (hu) 2012-10-12 2019-07-29 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
SI2906253T1 (sl) 2012-10-12 2018-11-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo proti PSMA
HUE045435T2 (hu) 2012-10-12 2019-12-30 Medimmune Ltd Pirrolobenzodiazepinek és konjugátumaik
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
WO2014057120A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués anticorps - pyrrolobenzodiazépine
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
AU2013328625B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EA027910B1 (ru) 2013-03-13 2017-09-29 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
CA2905181C (fr) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines et ses conjugues servant a fournir une therapie ciblee
MX2016001862A (es) 2013-08-12 2016-08-03 Genentech Inc Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento.
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
EP3054983B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépines
WO2015052534A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
RU2689388C1 (ru) 2013-12-16 2019-05-28 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами
EP3082875B1 (fr) 2013-12-16 2020-11-25 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3191134B1 (fr) 2014-09-12 2019-11-20 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA2957354A1 (fr) 2014-09-12 2016-03-17 Genentech, Inc. Anticorps et conjugues modifies genetiquement avec de la cysteine
MX2017003523A (es) 2014-09-17 2017-11-08 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas.
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
EP3226909A1 (fr) 2014-12-03 2017-10-11 Genentech, Inc. Composés d'amine quaternaire et conjugués anticorps-médicament de ceux-ci
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (fr) 2016-05-20 2017-11-23 Genentech, Inc. Conjugués anticorps-protac et procédés d'utilisation
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
EP3464280B1 (fr) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
WO2018031662A1 (fr) 2016-08-11 2018-02-15 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
KR20190110612A (ko) 2017-02-01 2019-09-30 모더나티엑스, 인크. 활성화 종양유전자 돌연변이 펩티드를 인코드하는 면역조절 치료 mrna 조성물
JP6671555B2 (ja) 2017-02-08 2020-03-25 アーデーセー セラピューティクス ソシエテ アノニム ピロロベンゾジアゼピン抗体複合体
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
AU2018255876B2 (en) 2017-04-18 2020-04-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
AU2018253948A1 (en) 2017-04-20 2019-09-19 Adc Therapeutics Sa Combination therapy with an anti-AXL Antibody-Drug Conjugate
MX2019015042A (es) 2017-06-14 2020-08-06 Adc Therapeutics Sa Regimen de dosificacion.
KR102270107B1 (ko) 2017-08-18 2021-06-30 메디뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
CN111788208B (zh) 2017-09-20 2023-11-24 Ph制药有限公司 泰兰他汀类似物
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP2022505450A (ja) 2018-10-24 2022-01-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法
CN113227119A (zh) 2018-12-10 2021-08-06 基因泰克公司 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023045A1 (fr) * 1993-04-07 1994-10-13 Boehringer Ingelheim International Gmbh Procede d'inhibition de la transcription de genes
WO1996017927A2 (fr) * 1994-12-05 1996-06-13 Karo Bio Ab Lignee cellulaire comportant des genes rapporteurs
US5932425A (en) * 1997-02-18 1999-08-03 Signal Pharmaceuticals, Inc. Compositions and methods for modulating cellular NF-κB activation
EP0955372A2 (fr) * 1998-03-20 1999-11-10 Suntory Limited Procédé de criblage de composés qui inhibent l'activation par NF-kappa B
WO2001072296A1 (fr) * 2000-03-27 2001-10-04 Astacarotene Ab Procede d'inhibition de l'expression de cytokines et de chimiokines inflammatoires

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023045A1 (fr) * 1993-04-07 1994-10-13 Boehringer Ingelheim International Gmbh Procede d'inhibition de la transcription de genes
WO1996017927A2 (fr) * 1994-12-05 1996-06-13 Karo Bio Ab Lignee cellulaire comportant des genes rapporteurs
US5932425A (en) * 1997-02-18 1999-08-03 Signal Pharmaceuticals, Inc. Compositions and methods for modulating cellular NF-κB activation
EP0955372A2 (fr) * 1998-03-20 1999-11-10 Suntory Limited Procédé de criblage de composés qui inhibent l'activation par NF-kappa B
WO2001072296A1 (fr) * 2000-03-27 2001-10-04 Astacarotene Ab Procede d'inhibition de l'expression de cytokines et de chimiokines inflammatoires

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 1 April 1992 (1992-04-01), retrieved from EBI Database accession no. M86377 *
DATABASE EMBL [online] 27 February 1992 (1992-02-27), retrieved from EBI Database accession no. M86699 *
DATABASE EMBL [online] XP002233369, retrieved from EBI Database accession no. BC000633 *
DOUVILLE E M J ET AL: "MULTIPLE CDNAS ENCODING THE ESK KINASE PREDICT TRANSMEMBRANE AND INTRACELLULAR ENZYME ISOFORMS", MOLECULAR AND CELLULAR BIOLOGY, vol. 12, no. 6, 1992, pages 2681 - 2689, XP009006945, ISSN: 0270-7306 *
KWON BYUNGSUK ET AL: "Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC.,, US, vol. 274, no. 10, 5 March 1999 (1999-03-05), pages 6056 - 6061, XP002147323, ISSN: 0021-9258 *
MILLS G B ET AL: "EXPRESSION OF TTK A NOVEL HUMAN PROTEIN KINASE IS ASSOCIATED WITH CELL PROLIFERATION", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 22, M86699, 1992, pages 16000 - 16006, XP002233366, ISSN: 0021-9258, Retrieved from the Internet <URL:EBI> *
WANG CUN-YU ET AL: "NK-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.", SCIENCE (WASHINGTON D C), vol. 281, no. 5383, pages 1680 - 1683, XP002233368, ISSN: 0036-8075 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
AU2002349784A8 (en) 2003-06-17
WO2003048202A2 (fr) 2003-06-12
AU2002349784A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
WO2003048202A3 (fr) Gène activant le facteur nucléaire kappa b
WO2004043382A3 (fr) Variants ameliores de l&#39;erythropoietine et methodes d&#39;utilisation
GB2292382B (en) Obesity (OB) peptides capable of modulating body weight of animals, allelic variants, analogs and fragments thereof, derivatives, nucleic acid sequences, vect
WO1999053040A3 (fr) Sequences d&#39;acide nucleique humain provenant de tissu de tumeur ovarienne
WO2002061076A1 (fr) Proteine associee a l&#39;adiponectine
WO2002044320A3 (fr) Genes humains de l&#39;elongase, leurs utilisations et composes destines a leur modulation
IL135688A0 (en) Human checkpoint kinase, hcds1, compositions and methods
WO2002077171A3 (fr) Proteines kinases humaines isolees, molecules d&#39;acides nucleiques codant ces proteines kinases, et utlisations correspondantes
WO2003042362A3 (fr) Pgc-1$g(b), un nouvel homologue du pgc-1 et leurs utilisations
WO2003031598A3 (fr) Sequences d&#39;acides nucleiques et d&#39;acides amines codant des polypeptides de facteur viii a expresseur a haut rendement et leurs procedes d&#39;utilisation
WO2000061742A3 (fr) Traitement d&#39;une insuffisance cardiaque
WO2004069200A3 (fr) Inhibiteurs specifiques de l&#39;activation de nfat par la calcineurine et leur utilisation en traitement de maladies immunologiques
EP1281763A3 (fr) FACTEUR DE TRANSCRIPTION &#34;Early growth response-1&#34; (EGR-1)
AU7001994A (en) Mutant polypeptide of protein kinase c, nucleic acid sequences coding for said polypeptide and use thereof
WO1998011234A3 (fr) Proteines kinases humaines
EP0816504A3 (fr) Facteur d&#39;activation des plaquettes acétylhydrolase, et gène codant celui-ci
WO2000040723A3 (fr) Methodes et produits servant a l&#39;administration d&#39;acides nucleiques
WO2003104277A3 (fr) Gene d&#39;activation de stat6
WO2002040683A3 (fr) Proteines kinase humaines isolees, molecules d&#39;acides nucleiques codant pour des proteines kinase humaines et utilisations
WO2001092496A3 (fr) Proteines kinases humaines isolees, molecules d&#39;acide nucleique codant pour ces proteines kinases humaines et utilisations de celles-ci
WO2004078112A3 (fr) Gene induisant l&#39;apoptose
WO2004072277A3 (fr) Gene associe a la phosphorylation d&#39;elk1
EP0816498A3 (fr) Récepteur pour acide aminé excitateur et acides nucléiques liés
WO2002018536A3 (fr) Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques
WO1996027015A3 (fr) Un nouveau gene pour une proteine kinase associee avec une resistance multiple aux medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase